ARDX logo

ARDX
Ardelyx Inc

19,275
Mkt Cap
$1.69B
Volume
8.08M
52W High
$8.40
52W Low
$3.21
PE Ratio
-26.71
ARDX Fundamentals
Price
$7.30
Prev Close
$6.88
Open
$7.14
50D MA
$6.04
Beta
1.00
Avg. Volume
3.2M
EPS (Annual)
-$0.2556
P/B
10.07
Rev/Employee
$832,965.23
$1,348.49
Loading...
Loading...
News
all
press releases
FY2030 Earnings Forecast for Ardelyx Issued By HC Wainwright
Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Research analysts at HC Wainwright cut their FY2030 earnings per share estimates for Ardelyx in a research note issued on Friday, May 1st. HC Wainwright analyst M. Caufield now anticipates that the biopharmaceutical company will earn $1.60 per share for th...
MarketBeat·16h ago
News Placeholder
More News
News Placeholder
AIGH Capital Management LLC Purchases 951,500 Shares of Ardelyx, Inc. $ARDX
AIGH Capital Management LLC lifted its position in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 479.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,150,000 shares of the biopharmaceutical company's...
MarketBeat·3d ago
News Placeholder
Ardelyx (NASDAQ:ARDX) Shares Gap Down After Earnings Miss
Ardelyx (NASDAQ:ARDX) Shares Gap Down Following Weak Earnings...
MarketBeat·3d ago
News Placeholder
Ardelyx (NASDAQ:ARDX) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS
Ardelyx (NASDAQ:ARDX - Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing the consensus...
MarketBeat·4d ago
News Placeholder
Ardelyx (ARDX) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·4d ago
News Placeholder
Ardelyx (ARDX) Reports Q1 Loss, Beats Revenue Estimates
Ardelyx (ARDX) delivered earnings and revenue surprises of -15.39% and +3.24%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Ardelyx Q1 Earnings Call Highlights
Ardelyx (NASDAQ:ARDX) executives said the company entered 2026 with "another significant year of growth" underway, highlighting strong first-quarter demand for its IBS-C product IBSRELA and continued momentum for kidney disease drug XPHOZAH, while also advancing pipeline efforts aimed at expanding t...
MarketBeat·4d ago
News Placeholder
Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·4d ago
News Placeholder
Ardelyx Target of Unusually Large Options Trading (NASDAQ:ARDX)
Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) was the target of unusually large options trading on Thursday. Stock investors acquired 7,048 call options on the stock. This represents an increase of...
MarketBeat·4d ago
News Placeholder
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·6d ago
<
1
2
...
>

Latest ARDX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.